Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 5/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.32 |
| ▸ | TUBB | P07437 | 2/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.32 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.32 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.32 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.32 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.32 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074143 | 0.99 | TDP1 (0.36) | EGFRTDP1MAOBCETPTUBB4A | |
| SCHEMBL7069086 | 0.95 | TDP1 (0.37) | EGFRTDP1MAOBHDAC3SMN1; SMN2 | |
| SCHEMBL7072917 | 0.94 | EGFR (0.35) | EGFRTDP1CETPTUBB4ATUBB | |
| SCHEMBL7076366 | 0.93 | TDP1 (0.34) | EGFRTDP1HDAC3SMN1; SMN2KDM4E | |
| SCHEMBL7072813 | 0.90 | MAOB (0.38) | TDP1MAOBSMN1; SMN2MAPTKDM4E | |
| SCHEMBL7070270 | 0.89 | TDP1 (0.35) | EGFRTDP1MAOBHDAC3SMN1; SMN2 | |
| SCHEMBL7075697 | 0.84 | MAOB (0.40) | MAOBHDAC3SMN1; SMN2MAPTKDM4E | |
| SCHEMBL7070708 | 0.84 | MAOB (0.33) | MAOB | |
| SCHEMBL7072969 | 0.84 | MAOB (0.32) | MAOB | |
| SCHEMBL7073495 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109730-A1 | Transition metal compound, addition polymerization catalyst component, addition polymerization catalyst and process for production of olefin polymer | NABIKA MASAAKI (JP) | 2003-06-12 | — | — | US | disclosed |
| US-6528671-B1 | Such as cyclopentadienyl-trimethylphosphineimine-1,4-di-phenyl butandiene titanium complex; copolymerization of ethylene with other alpha-olefins | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109730-A1 | Transition metal compound, addition polymerization catalyst component, addition polymerization catalyst and process for production of olefin polymer | ARL1, AP2M1, AP1M1 | EGFR 1661/4885TDP1 4039/4885MAOB 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.